{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:51:39Z","timestamp":1767145899922,"version":"build-2238731810"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gore.2020.100554","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T12:06:37Z","timestamp":1582632397000},"page":"100554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Selection of HER2\/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Silvia","family":"Pelligra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-334X","authenticated-orcid":false,"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Zeybek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2020.100554_b0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gore.2020.100554_b0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2020.100554_b0015","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.gore.2020.100554_b0020","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2020.100554_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of Trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2020.100554_b0030","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2020.100554_b0035","unstructured":"National Comprehensive Cancer Network, 2019. NCCN Clinical Practice Guidelines in Oncology-Uterine Neoplasms. Version 4.2019."},{"key":"10.1016\/j.gore.2020.100554_b0040","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2020.100554_b0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jamcollsurg.2012.09.007","article-title":"Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?","volume":"216","author":"Greer","year":"2013","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.gore.2020.100554_b0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","article-title":"Intratumoral heterogeneity of HER2\/neu in breast cancer\u2013a rare event","volume":"13","author":"Hanna","year":"2007","journal-title":"Breast J."},{"key":"10.1016\/j.gore.2020.100554_b0055","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.12998\/wjcc.v7.i15.1964","article-title":"HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer","volume":"7","author":"Kaito","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.gore.2020.100554_b0060","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","author":"Rottmann","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.gore.2020.100554_b0065","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1309\/AJCP51HCGPOPWSCY","article-title":"Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am. J. Clin. Pathol."}],"updated-by":[{"DOI":"10.1016\/j.gore.2021.100703","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:56:16Z","timestamp":1762480576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578920300205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":13,"alternative-id":["S2352578920300205"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2020.100554","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of HER2\/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2020.100554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100554"}}